Welcome to our dedicated page for Anebulo Pharmaceuticals news (Ticker: ANEB), a resource for investors and traders seeking the latest updates and insights on Anebulo Pharmaceuticals stock.
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) is a clinical-stage pharmaceutical company developing selonabant (ANEB-001), a CB1 receptor antagonist drug candidate for acute cannabis-induced toxicity and related cannabinoid-induced toxic effects. The ANEB news feed on Stock Titan aggregates the company’s press releases and market-moving updates so readers can follow how its development and corporate plans evolve over time.
News about Anebulo frequently centers on its clinical program for selonabant. The company has reported results from a Phase 2 proof-of-concept trial of oral selonabant in adults challenged with oral THC, as well as the initiation of a Phase 1 single ascending dose study of an intravenous formulation in healthy young adults. Updates often describe study design, safety and tolerability observations, and the role of selonabant as a potential antidote for acute cannabis-induced toxicity, particularly in pediatric patients.
Investors and observers can also find regulatory and funding developments in Anebulo’s news. The company has announced interactions with the U.S. Food and Drug Administration regarding the development path for IV selonabant, grant awards from the National Institute on Drug Abuse (NIDA) to support its clinical work, and private placement financings and loan arrangements that provide capital for ongoing research and development.
Another recurring theme in ANEB news is the company’s strategic and corporate actions, including a proposed going private transaction, a previously announced reverse stock split structure, and a later decision to pursue a voluntary self-tender offer to repurchase shares as part of its plan to reduce the number of stockholders. By reviewing the ANEB news page, readers can track clinical milestones, regulatory interactions, grant funding, financing events, and corporate governance decisions that Anebulo discloses through its press releases.
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) announced its financial results for the fiscal year ending June 30, 2021. The company reported a net loss of $30.25 million, or $(2.83) per share, compared to a net loss of $174,637, or $(0.01) per share, in the previous year. Key highlights include the manufacturing of ANEB-001 capsules for a Phase 2 clinical trial, formation of a Scientific Advisory Board, and successful IPO raising $21.5 million. Management expects to initiate the Phase 2 trial for acute cannabinoid intoxication in Q4 2021, with topline results expected in H1 2022.
Anebulo Pharmaceuticals (ANEB) announced the successful completion of manufacturing its lead drug, ANEB-001, for an upcoming Phase 2 clinical trial targeting acute cannabinoid intoxication. The capsules, available in 10mg and 50mg, comply with Good Manufacturing Practices. CEO Daniel Schneeberger highlighted the significance of ANEB-001 in addressing a growing issue, with over 1.7 million cannabinoid-related emergency visits in 2018, increasing by 15% annually. The Phase 2 study is set to commence ahead of schedule, with initial results expected in the first half of next year.
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company, announced participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company will present and hold one-on-one meetings with investors. A recorded presentation will be available on-demand starting September 13 on Anebulo’s website. Anebulo focuses on developing solutions for acute cannabinoid intoxication and substance addiction, with its lead candidate, ANEB-001, showing promising results in clinical trials.
Anebulo Pharmaceuticals (Nasdaq: ANEB) announced the formation of a Scientific Advisory Board (SAB) to enhance its clinical programs, co-chaired by experts Andrew Monte, M.D., Ph.D., and Arjun Chanmugam, M.D. The SAB will focus on advancing ANEB-001, aimed at treating acute cannabis intoxication, with a Phase 2 study expected to start in Q4 2021. The rise in cannabis-related emergency visits underscores the need for effective treatments. Anebulo's lead candidate is positioned uniquely in a growing market, with no direct competitors currently in advanced development.
Anebulo Pharmaceuticals reported significant developments and financial results for Q3 FY2021. The company successfully completed an IPO, selling 3,078,224 shares at $7.00, raising approximately $20.2 million. This funding supports ongoing operations and clinical trials for ANEB-001, aimed at treating cannabinoid intoxication, with a Phase 2 trial set to start in Q4 2021. Financially, the company incurred a net loss of $555,832, or $0.04 per share, with cash reserves at $3.3 million as of March 31, 2021. Anebulo expects the IPO proceeds to cover operations through December 2022.
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) has announced its initial public offering (IPO) pricing of 3 million shares at $7.00 each, aiming for gross proceeds of approximately $21 million before costs. The offering includes a 30-day option for the underwriter to purchase an additional 450,000 shares. Trading is set to begin on Nasdaq on May 7, 2021, with the offering closing around May 11, 2021. Anebulo focuses on solutions for cannabinoid overdose and addiction, with its lead product, ANEB-001, designed to reverse overdose effects within one hour.